Menstrual Blood HPV DNA and TAP1 gene Polymorphisms as Potential Biomarkers for Screening and Monitoring of Cervical Squamous Intraepithelial Lesion
Mené à Hong Kong à partir du sang menstruel collecté dans les serviettes hygiéniques de 137 témoins et 265 patientes présentant une néoplasie intra-épithéliale du col utérin ou une infection par le papillomavirus humain (HPV), cet essai évalue la performance d'un test, basé sur la recherche conjointe de l'ADN du HPV et de polymorphismes au niveau du gène TAP1 de l'ADN des participantes, pour détecter une lésion intra-épithéliale cervicale et identifier les patientes dont la lésion présente un risque faible de progression vers une lésion cancéreuse ou pré-cancéreuse de haut grade
Background : Human papillomavirus (HPV) is a known causative factor in the etiology of cervical cancer.
Methods : HPV DNA genotyping was performed in menstrual blood (MB) collected in napkins from patients with cervical intraepithelial neoplasia (CIN), HPV infection and sexually active apparently normal subjects. In the same patient cohort, MB TAP1 I333V and TAP1 D637G gene polymorphisms were examined.
Results : The sensitivity, specificity, positive and negative predictive values of HPV DNA to detect CIN or HPV infection was 83% (223/268), 98% (131/134), 99% (223/226) and (74%) 131/176, respectively. Moreover, HPV DNA was found in 24% (28/118) patients who had loop electrosurgical excision procedure treatment and 0% (0/76) HPV infected or CIN1 patient with proven recovery. On the other hand, the risk to develop high grade cervical intraepithelial neoplasia was significantly reduced for AG and GG genotypes when compared to AA genotype and for carriers with a G allele when compared to those with an A allele for both polymorphisms.
Conclusions : MB HPV DNA is a potential non-invasive marker for screening and monitoring of squamous intraepithelial lesion. Together with TAP1 I333V and TAP1 D637G gene polymorphisms, the combined test may be useful to stratify high risk patients for better follow-up strategies.
Clinical Trail : Trial number: 0378261
The Journal of Infectious Diseases , résumé, 2017